Enliven Therapeutics Inc. (ELVN)
NASDAQ: ELVNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ELVN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $3.42B
- EPS (TTM)
- -$1.69
- Dividend yield
- None
- 52-week range
- 14.79 – 62.32
- Day range
- 45.64 – 47.83
- Volume / Avg
- 933.55K / 1.36M
- Beta
- —
- Shares outstanding
- 73.60M
52-week range
ELVN stock today
Enliven Therapeutics (ELVN) closed at $46.53 on Nov 20, up 0.26% (+$0.12), versus the S&P 500's 3.70% decline. Shares are 25.3% below their 52-week high of $62.32, set on Aug 5, 2026 and 214.7% above the 52-week low of $14.79, in the middle of the past year's range. ELVN is up 202.1% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 113.9%.
Enliven Therapeutics has posted a net loss over the last twelve months (EPS of -$1.69), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Enliven Therapeutics
Company profileEnliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is based in Burlingame, California.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Richard A. Fair M.B.A.
- Headquarters
- Burlingame, CA
- Employees
- 65
- IPO year
- 2020
- Website
- enliventherapeutics.com
Financial highlights
Full financialsEnliven Therapeutics reported a net loss of $103.7 million, compared with a loss of $89.0 million a year earlier. Diluted earnings per share came in at -$1.83.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-103.69M | $-89.02M | $-71.58M | $-37.66M | $-51.38M |
| EPS (diluted) | $-1.83 | $-1.89 | $-2.01 | $-12.05 | $-2.37 |
Analyst forecast
ForecastConsensus (14 analysts)
strong_buy
Avg. price target
$74.33+59.75%
- Strong buy 3
- Buy 11
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 11, 2026
- EPS actual vs est.
- $-0.36 vs $-0.48
- Surprise
- +25.00%
ELVN news
All ELVN news- Enliven Therapeutics GAAP EPS of -$0.36Seeking Alpha
- Enliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business UpdatePR Newswire
- Enliven Appoints Former Antiva CEO Kristine Ball To Board As Relcobatinib Nears Phase 3 LaunchNasdaqELVN, ET
- Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this YearPR Newswire
Enliven Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| IRONDisc Medicine Inc. | 75.14 | -1.27% | $3.42B | vs ELVN |
| VRDNViridian Therapeutics Inc. | 29.96 | -4.71% | $3.40B | vs ELVN |
| PBLSParabilis Medicines Inc. | 27.44 | -0.67% | $3.44B | vs ELVN |
| AMLXAmylyx Pharmaceuticals Inc. | 26.02 | -0.69% | $3.35B | vs ELVN |
| ARQTArcutis Biotherapeutics Inc. | 26.36 | -2.98% | $3.33B | vs ELVN |
| XENEXenon Pharmaceuticals Inc. | 37.04 | -1.38% | $3.64B | vs ELVN |
| OGNOrganon & Co. | 13.89 | -0.14% | $3.65B | vs ELVN |
| ABCLAbCellera Biologics Inc. | 9.69 | -7.45% | $3.16B | vs ELVN |
Indexes, lists and sector
Enliven Therapeutics stock FAQ
What is Enliven Therapeutics's stock price today?
ELVN last traded at $46.53 as of Nov 20, 4:00 PM EST, up 0.26% on the day. Prices are delayed at least 15 minutes.
Who is Enliven Therapeutics's CEO?
Mr. Richard A. Fair M.B.A. is the chief executive officer of Enliven Therapeutics Inc., which has about 65 employees.
What is the ELVN 52-week high?
The 52-week high for ELVN is $62.32 and the 52-week low is $14.79. The stock is currently 25.3% below its high.